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CD8+ T cell recognition of virus-infected cells is char-
acteristically restricted by major histocompatibility
complex (MHC) class I, although rare examples of
MHC class II restriction have been reported in Cd4-
deficient mice and a macaque SIV vaccine trial using
a recombinant cytomegalovirus vector. Here, we
demonstrate the presence of human leukocyte anti-
gen (HLA) class II-restricted CD8+ T cell responses
with antiviral properties in a small subset of HIV-in-
fected individuals. In these individuals, T cell recep-
tor b (TCRb) analysis revealed that class II-restricted
CD8+ T cells underwent clonal expansion and medi-
ated killing of HIV-infected cells. In one case, these
cells comprised 12% of circulating CD8+ T cells,
and TCRa analysis revealed two distinct co-ex-
pressed TCRa chains, with only one contributing to
binding of the class II HLA-peptide complex. These
data indicate that class II-restricted CD8+ T cell re-
sponses can exist in a chronic human viral infection,
and may contribute to immune control.
INTRODUCTION
Antigen-specific CD8+ T cells are a major defense against
invading viruses, killing infected cells harboring non-self pro-Immunity 45, 917–930, Octo
This is an open access article undteins. The first step in this process involves T cell receptor
(TCR) recognition of virus-derived peptides presented on the
surface of infected cells by molecules of the major histocompat-
ibility complex (MHC) or human leukocyte antigen (HLA) in hu-
mans. The dominant paradigm of T cell recognition dictates
that CD8+ T cells recognize viral peptides of 8–11 amino
acids in length bound to MHC class I molecules, whereas
CD4+ T cells recognize peptides of 12 or more amino acids
restricted by MHC class II (Neefjes et al., 2011). During thymic
selection, double-positive T cells undergo a maturation process
where they are selected as either CD8+ T cells or CD4+ T cells de-
pending on TCR binding to peptide complexed with MHC class I
or class II, respectively. However, in certain cases, T cells with
atypical modes of MHC restriction have been reported. CD8+
T cell responses restricted by MHC class II have been described
in approximately a dozen published reports over the past two de-
cades. These responses have been observed in Cd4-deficient
mice, where the complete absence of CD4+ T cells led to the
unexpected expansion of CD8+ T cells restricted by class II
(Matechak et al., 1996; Mizuochi et al., 1988; Pearce et al.,
2004; Shimizu and Takeda, 1997; Suzuki et al., 1994; Tyznik
et al., 2004), and in mouse models of transplantation (Hirosawa
et al., 2011). In humans, reports have also described alloreactive
CD8+ T cell responses that cross-recognize HLA class I and II
(Heemskerk et al., 2001; Rist et al., 2009), indicating that uncon-
ventional HLA and TCR interactions may be an important feature
of allorecognition.
Remarkably, virus-specific CD8+ T cells restricted by MHC
class II were recently found to be the immunodominant
responses detected in the context of immunization with aber 18, 2016 ª 2016 The Author(s). Published by Elsevier Inc. 917
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
recombinant rhesus cytomegalovirus (RhCMV) vector in a ma-
caque simian immunodeficiency virus (SIV) vaccine model (Han-
sen et al., 2013), which also induced non-classical MHC-E
restricted CD8+ T cell responses (Hansen et al., 2016). In this
setting, the induction of CD8+ T cells with unconventional MHC
restriction was predominantly under the genetic control of the
strain 68-1 RhCMV vector and the epitopes targeted by these re-
sponses did not overlap with traditional MHC class I-restricted
responses. These studies demonstrate that unconventional
CD8+Tcell responses canbeelicited byengineeredRhCMVvac-
cine vectors and suggest that these responsesmay contribute to
the control of viral replication (Ranasinghe and Walker, 2013).
The extent to which HLA class II-restricted CD8+ T cell re-
sponses play a role in natural human immunity is unclear. To
address this in a chronic human viral infection, we screened a
large cohort of HIV-1-infected persons, including HIV controllers
who spontaneously control virus in the absence of antiretroviral
therapy. In these HIV controllers, we and others have shown
that class I-restricted CD8+ T cell responses, particularly HLA-
B-restricted responses targeting epitopes within the highly
conserved Gag protein, are associated with enhanced control
of viral replication (Emu et al., 2008; Fellay et al., 2007; Kaslow
et al., 1996; Kiepiela et al., 2004, 2007;Migueles et al., 2000; Per-
eyra et al., 2010). We now provide data showing induction of
class II HLA-DR-restricted CD8+ T cell responses in 3 of 101
HIV controllers tested. These class II-restricted CD8+ T cells ex-
hibited potent antiviral functions and were characterized by a
single dominant TCRb clonotype. In one individual, the HLA-
DR-restricted CD8+ T cells were immunodominant, comprising
12% of circulating CD8+ T cells. These data reveal the rare pres-
ence of atypical CD8+ T cells restricted by HLA-DR in a human
viral infection and indicate that T cells that violate immunologic
paradigms may shape human antiviral responses.
RESULTS
CD8+ T Cell Responses Restricted by HLA-DRB1 Exist in
Natural HIV Infection
Virus-specific CD8+ T cells typically recognize infected cells
through presentation of processed viral peptides on HLA class I
molecules, but class II-restricted responses have been detected
in some experimental systems and in the context of CMV vector
immunization in a macaque SIV vaccine model (Hansen et al.,
2013). In order to determine whether such responses exist in a
chronic human viral infection, we screened 129 people with un-
treated HIV-1 infection, all of whom expressed common class II
DRB1 alleles (Table S1). These included 101 untreated HIV con-
trollers whomaintained viral loads of less than 2,000RNAcopies/
mL plasma, as well as 28 individuals with untreated chronic HIV
infection exhibiting high viral loads.
Purified CD8+ T cells isolated from the peripheral bloodmono-
nuclear cells (PBMCs) of each subject were co-cultured with
mouse lymphoblastoid cell lines (LCL) stably expressing a single
recombinant human DRB1 molecule (Ranasinghe et al., 2013;
Southwood et al., 1998) matched to the donor, which had been
pulsed with individual overlapping peptides spanning the HIV
Gag protein. In initial screening, we identified an HIV controller,
subject 474723, inwhomasingleGagpeptidepresentedbyclass
II HLA DRB1*11:01 resulted in a robust interferon gamma (IFN-g)918 Immunity 45, 917–930, October 18, 2016Elispot response mediated by CD8+ T cells (Figure 1A). This tar-
geted peptide, Gag41 (YVDRFYKTLRAEQASQEV, aa 164–181),
is also known to be presented by DRB1*11:01 for CD4+ T cell
recognition in HIV-infected persons (Ranasinghe et al., 2013).
N- and C-terminal truncations indicated that presentation of
the FYKTLRAEQA peptide contained within the larger peptide
probably represented the core residues sufficient to elicit a
response (Figure 1B), with phenylalanine or tyrosine likely to be
the P1 anchor residue. Of the truncated peptides tested, the
most robust response was to the 16 amino acid peptide
DRFYKTLRAEQASQEV, which is expected to extend out of the
open class II binding groove. Class II restriction of the Gag41-
specific CD8+ T cell response was verified using an anti-HLA-
DR blocking antibody that inhibited IFN-g production in a dose-
dependent manner (Figure 1C).
To further confirm that this response was indeed mediated
by class II-restricted CD8+ T cells, and to more precisely
define the magnitude of the response, we constructed class II
tetramers with a truncated version of the Gag41 peptide
(DRFYKTLRAEQASQEV) that elicited the strongest Elispot
response. More than 12% of circulating CD8+ T cells were
DR11-Gag41 tetramer positive directly ex vivo (Figure 2A), which
was further confirmed by dual staining with both allophycocyanin
(APC)- andphycoerythrin (PE)-conjugated versionsof the tetramer
(Figure 2B).
Assessment of subjects by IFN-g Elispot revealed that this
was the only person in whom a class II-restricted CD8+ T cell
response could be detected to the Gag41 epitope, and this
was further confirmed by staining PBMCs of 76 persons ex-
pressing HLA DRB1*11:01 (including the 39 initially screened
by IFN-g Elispot) with DR11-Gag41 tetramers (Table S1). How-
ever, extended IFN-g Elispot screening and subsequent con-
struction of class II tetramers revealed two additional subjects,
270245 and 388031, in whom class II-restricted CD8+ T cell re-
sponses were detectable, both targeting a peptide designated
Gag37 (LNKIVRMYSPTSILD, aa 136–151) restricted by HLA-
DRB1*01:01. Although these responses were present at much
lower frequencies than the DR11-Gag41-restricted response,
dual APC and PE tetramer staining of the CD8+ T cell populations
using a DR01-Gag37 tetramer confirmed these were indeed
class II restricted (Figure 2B). All class II tetramers showed min-
imal non-specific staining when tested on HLA-matched HIV-
negative and HIV-positive subjects (Figure S1). Table S2 shows
HLA genotyping and clinical characteristics of these three sub-
jects with class II-restricted CD8+ T cell responses.
We next compared the magnitude and specificity of the class
II-restricted CD8+ T cells with the most immunodominant class
I-restricted Gag-specific CD8+ T cells in each of the three sub-
jects, using HLA tetramers (Figure 2C) and Elispot assays (Fig-
ure S2). In terms of magnitude, for subject 474723 the DR11-
Gag41-restricted response was immunodominant over all class
I-restricted Gag-specific responses tested, at 12% frequency
compared to a class I B57-KF11+ tetramer population of 2% fre-
quency ex vivo. In terms of specificity, there wasminimal overlap
between HLA class I and class II epitopes to which responses
were detected (Figure S3A). However, in the other two subjects,
the unconventional responses were subdominant. The DR01-
Gag37 epitope was adjacent to epitope B08-EI8 in subject
270245 and partially overlapped with immunodominant epitope
AB
C
Figure 1. Elucidation of a HLA Class II DRB1-Restricted CD8+ T Cell Response in HIV Controller 474723
(A) Representative IFN-gHLA-DR Elispot usingmagnetically enriched CD8+ T cells (FACS plot insert) co-culturedwith an LCL stably transfected with DRB1*11:01
(matching the HLA type of subject) pulsed with 66 overlapping peptides (OLPs) spanning the HIV Gag protein. Error bar represents SD.
(B) Representative IFN-g HLA-DR Elispot performed with N- and C-terminal peptide truncations presented on DRB1*11:01 LCL. Epitope FA10 within Gag41 is
highlighted in red.
(C) Representative flow cytometric intracellular cytokine secretion (ICS) assay with anti-HLA-DR antibody performed on whole PBMCs co-cultured with
DRB1*11:01 LCL.
See also Figures S1–S3 and Table S1.
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Figure 2. Detection of HLA Class II DRB1-Restricted CD8+ T Cell Responses in Three HIV Controllers by Class II Tetramers
(A) Representative FACS plots of HLA class II tetramer staining using fresh PBMCs. Bulk CD8+ T cells are shown in the absence and presence of DR11-Gag41
tetramer for subject 474723 and DR01-Gag37 tetramer for subjects 270245 and 388031.
(B) Representative FACS plot of dual PE and APC-conjugated class II tetramer staining.
(C) Representative FACS plots of class I tetramer staining.
All populations shown are gated on CD3+CD8+CD4CD19CD14CD56 live lymphocyte singlets.
See also Figures S1–S3 and Tables S1 and S2.B27-KK10 in subject 388031, yet each population was distinct
by class I and II tetramer staining (Figures S3B and S3C).
We next investigated the phenotypic characteristics of the sub-
ject-derived class II tetramer-positive CD8+ T cell populations
using flow cytometry (Figure 3A) and single-cell RNA sequencing
(scRNA-seq) (Figure 3B). We found that both CD8a and CD8b
were expressed at the protein and transcript levels. The class
II-restricted CD8ab+ T cells did not co-express CD4 protein or
mRNA. Next, we assessed the memory phenotype of these
responses. All three subjects exhibited antigen-experienced
effector memory phenotypes, although the degree of differentia-
tion was different for each subject. In 474723, the immunodomi-
nant DR11-Gag41-positive CD8+ T cells manifested an unusual
differentiation for HIV-specific CD8+ T cells: all tetramer-positive
cells exhibited a highly differentiated effector memory (Temra)
phenotype (CCR7CD45RA+) (Figure 3C). In contrast, the DR01-
Gag37-positive CD8+ T cells, which were subdominant in vivo
in both individuals, predominantly exhibited an effector memory
(Tem) phenotype (CCR7CD45RA). PD-1 expression was found
to be consistent with their memory phenotype (Figure S4).
Collectively, these data indicate that virus-specific CD8ab+
T cell responses restricted by HLA-DRB1 exist in the setting of920 Immunity 45, 917–930, October 18, 2016natural HIV infection, and although this is a rare event, such re-
sponses can represent an immunodominant HIV-specific CD8+
T cell response.
HLA Class II DRB1-Restricted CD8+ T Cells Lyse
Autologous HIV-Infected Targets Ex Vivo
Little is known about the function of CD8+ T cells restricted by
HLA class II, and particularly whether these cells have antiviral
properties. Therefore, we examined the expression of granzyme
B in class II-restricted CD8+ T cells by intracellular staining
and flow cytometry. The majority of class II tetramer+ CD8+
T cells from each subject was granzymeBhi when compared to
bulk CD8+ T cells (Figure 4A). Additionally, transcriptional
profiling conducted by scRNA-seq on tetramer-sorted single
cells confirmed that class II-restricted CD8+ T cells from all three
subjects expressed perforin, granzyme B, granzyme H, MIP-1b,
and RANTES (Figure 4B).
Previousstudieshaveshownproliferation in response toepitope
recognition to be associated with antiviral function (Horton et al.,
2006; Riou et al., 2014), so we next compared the proliferative ca-
pacity of class II-restricted CD8+ T cells with the most immunodo-
minant class I-restricted Gag-specific CD8+ T cell response in
A C
B
Figure 3. HLA Class II-Restricted CD8ab T Cells in Three HIV Controllers Exhibit Heterogeneous Memory Phenotypes
(A) Representative FACS plots denoting surface expression of CD8a and CD8b. Tetramer-positive expression is shown in red. Bulk CD3+CD4 T cells are shown
in gray. CD3+CD4+ T cells are shown in black.
(B) Violin plots denoting the distribution of single-cell expression levels of CD8a (CD8A), CD8b (CD8B), and CD4 RNA transcripts in unstimulated class II tetramer-
sorted CD8+ and CD4+ T cells estimated from single-cell RNA-seq. Abbreviation: TPM, transcripts per kilobase million. Statistical significance was determined
with Mann-Whitney-Wilcoxon test (***p < 0.001).
(C) Representative FACS plots showmemory phenotype of tetramer-positive HLA class I- and class II-restricted CD8+ T cells. All populations shown are gated on
tetramer+ CD3+CD8+CD4CD19CD14CD56 live lymphocyte singlets.
See also Figure S4.
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Figure 4. HLA Class II-Restricted CD8+ T Cells Exhibit Cytolytic Properties and Proliferative Capacity
(A) Representative FACS plots gated on unstimulated CD8+ T cells expressing intracellular granzyme B and tetramer in three HIV controllers. Tetramer pop-
ulations are gated on tetramer+CD3+CD8+CD4CD19CD14CD56 live lymphocyte singlets.
(B) Violin plots denoting the distribution of single-cell levels of Perforin, Granzyme B, Granzyme H, MIP-1b, and RANTES RNA transcripts in unstimulated class II
tetramer-sorted CD8+ T cells from three HIV controllers by scRNA-seq.
(C) Representative FACS plots gated on CD8+ T cells expressing CFSE and tetramer at day 7 after stimulation of bulk PBMCs from HIV controllers 474723 and
270245. Abbreviations: TPM, transcripts per kilobase million; PHA, phytohaemagglutinin.
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subjects 474723 and 270245, for whom sufficient samples were
available. The class II tetramer-positive cells demonstrated spe-
cific proliferation upon stimulation with cognate peptide (Fig-
ure 4C). Of note, class I tetramer-positive cells from subject
270245 showed populations that were carboxyfluorescein diace-
tate succinimidyl ester (CFSE+) positive yet tetramer negative,
possibly due to TCR downregulation or non-specific proliferation
induced by activation. These data demonstrate that DR11-
Gag41-positive CD8+ Temra cells and DR01-Gag37-positive
CD8+ Tem cells have substantial proliferative capacity.
We next generated class II-restricted CD8+ T cell clones from
subjects 474723 and 270245. These clones demonstrated spe-
cific, potent killing of autologous Epstein-Barr virus (EBV)-trans-
formed B cells (BCL) pulsed with the cognate class II peptide.
Additionally, the class II-restricted clones showed substantial
cytolytic activity against autologous CD4+ T cells super-infected
with HIV-1 NL4.3 as well as against CD14+ monocyte-derived
macrophages super-infected with vesicular stomatitis virus
G-protein (VSV-G) pseudotyped HIV-1 NL4.3-expressing GFP
(Figure 5A).
Thereafter, we tested the ability of class II-restricted CD8+
T cells to kill directly ex vivo and compared their antiviral efficacy
with the class I-restricted CD8+ T cell population (Figure 5B).
BCLs, used as target cells for this assessment, displayed equiv-
alent surface expression of HLA-ABC and HLA-DR (Figure S5).
The DR11-Gag41+ and B57-KF11+ populations from subject
474723, as well as the DR01-Gag37+ and the B08-EI8+ popula-
tions from subject 270245, were tetramer sorted from fresh
blood and then co-cultured with autologous BCL in a chromium
release assay. The class II-restricted CD8+ T cells from both
subjects demonstrated direct ex vivo specific killing of pep-
tide-pulsed BCL akin to that of the immunodominant class
I-restricted CD8+ T cell responses, indicating that these popula-
tions exhibit a similar killing efficiency (Figure 5B). Longer incu-
bation of Gag41-loaded target cells with either tetramer-sorted
CD8+ T cells or bulk CD8+ T cells from subject 474723 in a modi-
fied in Vitro Technique for Assessing Lysis (VITAL) assay resulted
in greater than 98% elimination of target cells over a 36 hr incu-
bation. The percentage of lysed target cells was similar to that
achieved with bulk CD8+ T cells co-cultured with KF11-loaded
target cells, whereas target cells loaded with a control peptide
were not eliminated (Figure S6).
We subsequently evaluated the ability of ex vivo isolated class
II-restricted CD8+ T cells to recognize and kill HIV-infected cells
displaying naturally processed HIV antigen resulting from pro-
ductive infection. Due to limited sample availability from subject
474723, we focused on autologous monocyte-derived macro-
phage targets that express naturally high levels of surface
HLA-DR. The monocyte-derived macrophages were super-in-
fected with a VSV-G-pseudotyped HIV-1 NL4.3 prior to co-cul-
ture with freshly isolated tetramer-sorted DR11-Gag41+CD8+
T cells. We observed that effectors lysed HIV-infected macro-
phages directly ex vivo, with 19%mean specific lysis compared
to 4% mean specific lysis in the control (p = 0.049) (Figure 5C).
Infection of viable macrophages, measured by GFP expression
or p24 staining, was >92% (Figure S5). These data demonstrate
that HIV-infected macrophages effectively process and present
naturally derived HIV peptide on the cell surface for recognition
by class II-restricted CD8+ T cells.As a further measure of potential CD8+ T cell-mediated anti-
viral function, we examined the sequence of the HLA-DR-
restricted epitope for evidence of immune selection pressure.
More than 80% of sequences in subject 474723 showed homol-
ogy to the Gag41 peptide sequence. However, almost 20% of
sequences exhibited a Q308H mutation within the Gag41
epitope (Figure 5D). Although the DR11-Gag41+ effectors and
the bulk CD8+ T cells effectively lysed BCL pulsed with wild-
type peptide, they showed no detectable lysis of the Q308H
peptide, consistent with this being a putative escape mutation.
There was no detectable CD8+ T cell response to B57-QW9
in this subject and prior sequencing of B57 controllers has not
detected any Q308H mutants (Migueles et al., 2000), indicating
that Gag41-specific T cells probably drive Q308H escape.
These data suggest that the DR11-Gag41-restricted T cells
may be capable of exerting immune selection pressure.
Taken together, our data assessing the cytolytic marker
expression, epitope-specific proliferative capacity, target cell
lysis, and immune selection pressure indicate that class II-
restricted CD8+ T cells demonstrate potent antiviral properties.
HLA Class II-Restricted CD8+ T Cells Are Constituted by
One Dominant TCRb Clonotype
To further define these HLA class II-restricted CD8+ T cell re-
sponses, we computationally reconstructed TCR using scRNA-
seq data from single tetramer-sorted class II-restricted CD8+
T cells from each of the three subjects. In each, we found that
the class II-restricted CD8+ T cell response was characterized
by expansion of a single TCRb clonotype (Figure 6).
The HLA class II-restricted CD8+ T cell responses identified
here are also immunodominant epitopes normally seen by con-
ventional class II-restricted CD4+ T cell responses (Ranasinghe
et al., 2012, 2013), so we next analyzed whether both CD4+ and
CD8+ T cells could bind the class II tetramers. The same class II
tetramers that recognized CD8+ T cells also stained ex vivo
CD4+ T cells, albeit very weakly in two of the three subjects (Fig-
ure 7A). These tetramer-positive CD4+ T cells were within the ex-
pected range for an epitope-specific response (Scriba et al.,
2005), yet the frequency of the class II-restrictedCD8+ T cell pop-
ulation intra-patientwasdramatically larger. Together, thesedata
reveal an immunological phenomenon inwhich conventionalHLA
class II-restricted CD4+ and unconventional class II-restricted
CD8+ T cells can bind the same peptide-HLA complex.
We next examined whether CD8+ and CD4+ T cells targeting
the same peptide-HLA had similar TCR rearrangements. Due to
sample availability and tetramer-positive CD4+ cell number con-
straints, we were limited to analysis of subject 474723. Because
we had already identified the TCRbV gene for the DR11-Gag41+-
restricted CD8+ T cells, we used the class II tetramers and a
TRBV2-specific fluorescent antibody to analyze both CD8+ and
CD4+populations (Figure 7B).Consistentwith the sequencing re-
sults, we found that the class II-restricted CD8+ population was
comprised of 99.9% TRBV2-positive cells, and that 73.9% of
the tetramer-positive CD4+ response was also TRBV2 positive.
We also computationally reconstructed TCRs using scRNA-
seq data from single DR11-Gag41 tetramer-sorted CD4+
T cells. We identified 22 TCRb sequences for the DR11-Gag41-
restricted CD4+ T cells. In contrast to the DR11-Gag41-
restricted CD8+, where there was only one dominant clonotype,Immunity 45, 917–930, October 18, 2016 923
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Figure 5. HLA Class II-Restricted CD8+ T Cells Lyse Autologous HIV-Infected Targets Ex Vivo and Exert Putative Immune Selection Pressure
In Vivo
(A) Summary data assessing specific lysis of target cells by class II-restricted CD8+ T cell clones from subjects 474723 and 270245 in a standard 6 hr chromium
release assay. Autologous targets included EBV-transformed BCL pulsed with peptide or no peptide, CD4+ T cells infected with the HIV strain NL4.3, and
monocyte-derived macrophages infected with VSV-G pseudotyped HIV NL4.3 encoding GFP, all at an effector to target cell ratio (E:T) of 1:1. Statistical sig-
nificance was determined using a paired t test.
(B) Summary data assessing specific lysis of target cells by ex vivo tetramer+ sorted HLA class I- and class II-restricted CD8+ T cells in a standard 6 hr chromium
release assay atmultiple E:T ratios. Ex vivo effector cells were derived from fresh blood and tetramer sortedwithin 12 hr of phlebotomy. As target cells, autologous
EBV-transformed BCL from subjects 474723 and 270245 were pulsed with cognate peptide or no peptide. Statistical significance was determined using a paired
t test.
(C) Summary data assessing specific lysis of autologous monocyte-derived macrophages pulsed with the cognate peptide Gag41 or infected with VSV-G
pseudotyped HIV NL4.3 encoding GFP by ex vivo DR11-Gag41 tetramer+ sorted CD8+ T cells from subject 474723 in a standard 6 hr chromium release assay at
an E:T ratio of 1:1.
(D) Deep sequencing of autologous virus in subject 474723. Mutation Q308H within the Gag41 epitope is boxed. Specific lysis of EBV-transformed BCL pulsed
with wild-type Gag41 peptide or the Q308H mutant peptide was tested in a standard 6 hr chromium release assay with ex vivo tetramer-sorted DR11-Gag41
tetramer+ sorted CD8+ T cells or bulk CD8+ T cells at a 1:1 E:T ratio.
All data points for each graph represent biological replicates in a single experiment. Error bars represent SD. See also Figure S6.we observed a more diverse response comprised of 16 different
clonotypes for the CD4+ T cells. Many clonotypes (13/22) used
the same TRBV2 gene but had different rearrangements, high-
lighted in green in Figure 6. Thus in subject 474723, we found
that TRBV2 is preferentially selected by both CD8+ and CD4+
T cell responses that target this class II HLA-peptide complex.
From characterization of the TCRa gene usages of both DR11-
Gag41 CD4+ and CD8+ T cells using computational reconstruc-924 Immunity 45, 917–930, October 18, 2016tion from the scRNA-seq data, we obtained TCRa sequences
from 71 and 17 single cells of the CD8+ and CD4+ populations,
respectively. We found that the CD8+ T cell repertoire had only
one TCRb clonotype comprised of gene segments TRBV2,
TRBJ2-7, and TRBC2, but two distinct TCRa clonotypes. One
was comprised of gene segments TRAV6, TRAJ39, and TRAC
and the second was comprised of TRAV26-1, TRAJ16, and
TRAC. However, the CD4+ repertoire had ten different TCRb
Figure 6. TCR Repertoires of HLA Class II-Restricted CD8+ T Cells Are Comprised by Monoclonal Responses
Ex vivo class II-restricted CD8+ and CD4+ T cells were tetramer sorted to be used for scRNA-seq and subsequent TCR reconstruction. TCR b and a clonotypes
are shown for each identified subject, with relevant sequences highlighted in color. Relative b and a clonotype frequency was calculated as follows: number of
cells with a particular clonotype / total number of cells fromwhich any TCRVb or Va genewas reconstructed, respectively. Abbreviation: CDR3, complementarity-
determining region 3.clonotypes (Figure 6). Because this analysis was performed from
sorted DR11-Gag41+ T cells at a single cell per well for down-
stream RNA-seq and TCR reconstruction, we could identify
that the two different TCRa chains, TRAV6-TRAJ39 and
TRAV26-TRAJ16, were co-expressed within the same CD8+
T cell, consistent with incomplete allelic exclusion of TCRa dur-
ing thymic selection (Figure 7C).
Both TRAV26 and TRAV6 sequences in the class II-restricted
CD8+ T cells were productively rearranged. Therefore, to test
for functionality, we cloned the TCR constructs and generated
two TCR hybridomas that expressed either TRAV6 with
TRBV2 or TRAV26 with TRBV2. Both TRAV26 and TRAV6
were able to refold properly to pair with the b, TRBV2, and be
expressed on the surface of cells. However, we found that
only TRAV6 (shown in red), but not TRAV26 (shown in blue),
bound to the DR11-Gag41 complex when paired with TRBV2
(Figure 7D). To evaluate the functionality of the hybridomas,
we measured interleukin 2 (IL-2) secretion after stimulation
with the Gag41 peptide. We found that TRAV6 with TRBV2,
but not TRAV26 with TRVB2, was able to produce IL-2 in a
dose-dependent manner in response to peptide (Figure 7E).
Both assays showed that only the TRBV2 with TRAV6 pair
was functional, confirming that TRAV6 was necessary for TCR
recognition of DR11-Gag41 complex. Next, we produced solu-
ble TCR of TRAV6 with TRBV2 to assess the binding kinetics to
DR11-Gag41 using surface plasmon resonance. The interaction
of TRAV6 and TRBV2 with DR11-Gag41 showed an overall
dissociation affinity constant (KD) of 8.1 mM, which is typical
for MHCII-peptide-specific TCRs (Figure 7F; van der Merwe
and Davis, 2003). Collectively, these data indicate that these
class II-restricted CD8+ cells express two different TCRa genes,
only one of which targets HIV epitopes, possibly due to ineffi-
cient allelic exclusion during thymic T cell development, a
phenomenon that is known to occur for the TCRa in 20% of
conventional T cells (Mason, 1994).Collectively, our data from sequencing the TCRb revealed that
class II-restricted CD8+ T cells are monoclonal in all three sub-
jects. Additionally, in subject 474723, a specific TRBV is prefer-
entially selected and shared by CD8+ and CD4+ T cells targeting
the same DR11-Gag41 complex. Finally, we showed that DR11-
Gag41-specific CD8+ express two distinct TCRa chains, with
only one contributing to the binding of this class II HLA-peptide
complex.
DISCUSSION
CD8+ T cells play a critical role in control of viremia, typically
through the recognition and killing of infected cells presenting
pathogen-derived peptides on HLA class I molecules. Yet,
whether CD8+ T cells restricted by HLA class II exist in natural
human viral infections and exert antiviral functions is unclear.
Here, we report the existence of CD8+ T cells that recognized
HIV Gag peptides presented on HLA class II. Although these
were rare events—found in 3% of the HIV controller population
in this study—in one individual the class II-restricted CD8+
T cells were the most immunodominant CD8+ response de-
tected, encompassing 12% of circulating CD8+ T cells. These
cells exhibited high proliferative capacity and potent lysis of
target cells and may have imposed selection pressure for the
generation of viral escapemutants, comparable to the well-char-
acterized antiviral efficacy of class I-restricted CD8+ T cells.
These data illustrate that paradigm-violating HLA class II-
restricted CD8+ T cells can be elicited in a chronic human viral
infection. Moreover, our findings reveal an unexpected flexibility
in CD8+ T cell recognition and demonstrate that the paradigm of
CD8+ T cell restriction by HLA class I molecules is not absolute in
human anti-viral immune responses.
Our analysis also revealed that class II-restricted CD8+ T cells
demonstrated atypical patterns of TCR usage that challenge the
current paradigm of T cell recognition. First, in all three subjects,Immunity 45, 917–930, October 18, 2016 925
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Figure 7. DR11-Gag41-Restricted CD8+ T Cells Are Constituted by One Dominant TCRb Clonotype yet Co-express Two Different TCRa
Chains
(A) Representative FACS plots of CD8+ T cell responses (top) and CD4+ T cell responses (bottom) for each of three subjects stained with the same class II
tetramers. PBMCs from subject 474723 were stained with DR11-Gag41 tetramer and those from subjects 270245 and 388031 with DR01-Gag37. All populations
shown are gated on CD3+CD19CD14CD56 live lymphocyte singlets.
(B) Representative FACS plot gated on CD8+ and CD4+ T cells from subject 474723 stained with a fluorescently conjugated TCRb TRVB2*01-specific antibody
and DR11-Gag41 tetramer. Populations shown are gated on DR11-Gag41 tetramer+CD3+CD19CD14CD56 live lymphocyte singlets.
(C) Heatmap showing expression of a and b TCR V, J, and C segments (rows) from individual cells (columns) from subject 474723. Ex vivo DR11-Gag41-specific
CD8+ T cells were tetramer sorted as single cells for scRNA-seq and subsequent TCR reconstruction.
(D) Representative FACS plot of TRAV6- and TRBV2-expressing hybridomas (left) and TRAV26- and TRBV2-expressing hybridoma (right) stained with a
fluorescent HLA-DR11-Gag41 tetramer (red or blue) or no tetramer (black).
(E) Left: T cell hybridomas expressing no TCR (black) or transduced with either the TRAV6 with TRBV2 TCR (red) or the TRAV26 with TRBV2 TCR (blue) were
stimulated non-antigen specifically overnight with a plate bound anti-TCR CbMab to confirmed the signaling ability of the TCRs. Supernatants were assayed for
secreted IL-2. Right: The same T cells were cultured overnight with an HLA-DR11-bearing LCL and various concentrations of the Gag-41 peptide. Supernatants
were assayed for secreted IL-2 using the IL2-dependent cell line HT2.
(F) Biotinylated HLA DR11-Gag41 (2,000 RU) was captured in a flow cell of a BIAcore streptavidin biosensor chip. Various concentrations of soluble TRAV6 and
TRBV2 were injected for 80 s, and the affinity was calculated with BIAEvaluation 4.1 software after correction for the fluid phase RU signal.
Abbreviation: FPKM, fragments per kilobase million.the class II-restricted CD8+ T cell response was characterized by
expansion of a single TCRb clonotype, rather than the typically
oligoclonal TCR repertoires observed for epitope-specific class
I-restricted CD8+ T cells (Almeida et al., 2007; Chen et al.,
2012; Mendoza et al., 2012). Second, we observed a phenome-
non in which class II-restricted CD8+ T cells targeted the same
HLA-peptide complex as conventional CD4+ T cells. Our data
indicated that, in one subject, this was associated with preferen-
tial selection of TRBV2 usage in all CD8+ T cells and most CD4+
T cells targeting the DR11-Gag41 complex. Although other
studies have demonstrated TCRb ‘‘public clonotypes’’ among vi-926 Immunity 45, 917–930, October 18, 2016rus-specific CD8+ (Iglesias et al., 2011) or CD4+ (Benati et al.,
2016) T cells in unrelated individuals, here TCR sharing occurred
between antigen-specific CD8+ and CD4+ T cells within an indi-
vidual. Lastly, analysis of the TCRa chain revealed expression
of two a chains. However, only TRAV6 in combination with
TRBV2 was able to bind DR11-Gag41. We hypothesize that
the second a chain (TRAV26) in combination with TRBV2 may
have interacted with a class I molecule occupied by a self
peptide or foreign peptide at sufficient affinity, leading to its
positive selection resulting in differentiation into a CD8+ single-
positive T cell in the thymus with subsequent migration into the
periphery. Subsequent HIV infection may have then fortuitously
selected this peripheral CD8+ T cell clone in the context of the
DR11-Gag41 peptide (via its TRAV6 TCR specificity), resulting
in an expanded population of memory cells with potent antiviral
function. Taken together, our data imply that these unconven-
tional CD8+ T cells exhibit distinctive TCR characteristics and
suggest a mechanistic explanation as to how class II-restricted
CD8+ T cells can be selected; this phenomenon may also in
part explain the rarity of these responses.
Our data revealed that Gag-specific CD8+ T cells restricted by
HLA-DR had a cytotoxic T lymphocyte-like phenotype and effec-
tively killed autologous HIV-infected cells. HLA-DR-restricted
CD8+ T cells may confer multiple advantages in the context
of HIV infection. Unconventional restriction may allow CD8+
T cells to exert antiviral effector functions on infected macro-
phages and activated CD4+ T cells that typically express high
levels of HLA-DR. Cytotoxic CD8+ T cells restricted by HLA-DR
may also have an advantage in settings where HIV Nef-mediated
class I downregulation may impair recognition (Schwartz et al.,
1996). Furthermore, targeting of the Gag-37 and -41 peptides
may allow HLA-DR-restricted CD8+ T cells to target a virus that
has already escaped within epitopes restricted by conventional
CD8+ T cells. Yet, it is difficult to assess the contribution of
these unconventional CD8+ T cells to immune control. Subjects
474723 and 388031 express class I alleles B*57:03 and B*27:05,
respectively, which are strongly associated with HIV-1 control
(Carrington andWalker, 2012). Subject 270245 lacks these ‘‘pro-
tective’’ class I alleles and exhibits a DR01-Gag37-restricted
CD8+ T cell response with demonstrable antiviral efficacy
ex vivo. This raises the possibility that DR01-Gag37-restricted
CD8+ T cell antiviral functions, in addition to CD8+ T cell re-
sponses restricted by ‘‘non-protective’’ class I alleles, may
contribute to immune control in this individual. Further studies
aimed at inducing unconventional CD8+ T cell responses in
healthy humans would be required to determine their in vivo anti-
viral efficacy and delineate their overall contribution to control of
viral replication.
The potential relevance of class II-restricted CD8+ T cell re-
sponses is underscored by results from an SIV vaccine trial. In
monkeys immunized with strain 68-1 RhCMV vector and chal-
lenged with pathogenic SIV, two-thirds of the CD8+ T cell re-
sponses recognized a wide breadth of SIV Gag epitopes bound
to class II molecules (Hansen et al., 2013). Induction of class II-
restricted CD8+ T cells, which occurs in every immunized animal,
is a consequence of the absence of two viral genes (Rh157.5 and
Rh157.6) in the strain 68-1 vector, as indicated by the fact that
repair of these two genes reverts CD8+ T cell responses back
to class I restriction (Hansen et al., 2013). The Rh157.5 and
Rh157.4 gene products are part of a RhCMV receptor for non-fi-
broblasts and their absence changes the cellular tropism of the
vector, making it more fibroblast-tropic, which in turn is thought
to change the priming environment to favor generation of class II-
restricted CD8+ T cells. As the modified vector does not change
the CD8+ naive T cell repertoire, the implication of these findings
is that atypical priming conditions efficiently prime pre-existing
CD8+ T cells with cross-reactive TCR. Class II-restricted CD8+
T cell responses were also recently seen in 4 of 12 unvaccinated
SIV-infected monkeys with controlled viremia (1 such response
per ‘‘SIV contoller’’ monkey; 4 MHC-II-restricted responses outof a total of 180 epitope-specific responses evaluated) (Hansen
et al., 2016). These data support our findings that memory Gag-
specific CD8+ T cell responses restricted by class II can be eli-
cited in natural viral infection, and as such must exist in the naive
T cell repertoire of at least some humans and macaques. Thus it
may be possible to induce and expand these responses in
healthy uninfected subjects. However, we currently do not
know whether class II-restricted CD8+ T cells responses actually
contribute to viral control in vivo in either the CMV vector-
induced or natural SIV/HIV infection models.
Although we showed that class II-restricted CD8+ T cells can
exist in natural HIV infection, we note a number of limitations in
this study. We detected only a single Gag-specific CD8+ T cell
response restricted to HLA-DRB1 in each of three HIV controller
individuals and in none of the HIV chronic progressors. The low
number of responses detected may be due to the method of
screening, a modified IFN-g Elispot using LCL stably expressing
a single recombinant HLA-DR molecule. Arguably, the reliance
on IFN-g detection may thwart detection of unconventional
CD8+ T cell responses if they do not secrete this cytokine. To
circumvent this limitation, we also screened HIV-infected indi-
viduals with class II tetramers, but CD8+ T cell responses
were found only in the aforementioned three individuals, con-
firming that the modified Elispot is unlikely to have missed
low-level responses. Because the macaque studies evaluated
only SIV Gag-specific CD8+ T cell responses restricted by
Mamu-DRB, we focused this study on HIV Gag-specific CD8+
T cell responses restricted by common HLA-DRB1 alleles. We
did not test for class II-restricted CD8+ T cell responses to other
HIV proteins, or to class II DRB4, DRB5, DP, or DQ. Another
constraint in our study was limited sample availability and low
numbers of tetramer-positive cells, so in some parts of this
study, we primarily focused on the characterization of subject
474723. This subject demonstrated potent killing of target cells
ex vivo, showed putative evidence of viral escape in vivo, and
exhibited unique TCR features. However, given the rarity of
these unconventional CD8+ T cell responses, it is not clear
whether we can make generalizations between class I- and
class II-restricted CD8+ T cells. Indeed, further work will be
required to determine whether these unconventional responses
represent a distinct subset of HIV-responsive cells or represent
class I-restricted CD8+ T cells that simply happen to bear TCR
that cross-react with Gag peptide presented by class II. Finally,
whether these results can be extrapolated to unconventional
T cells in other pathogenic infections or vaccine settings will
require additional study.
In summary, these data reveal rare class II-restricted CD8+
T cell responses with potent antiviral properties and clonal
expansion in the setting of a natural human viral infection, chal-
lenging current paradigms of T cell recognition and restriction.
Our findings suggest greater flexibility in CD8+ T cell recognition
and restriction, which is likely modulated by TCR cross-reactivity
and which may be important for immunological outcomes. Thus,
these data not only enhance our understanding of the basic
immunology of TCR-peptide-HLA interactions, but also may be
important for future T cell-based vaccine design and immuno-
therapeutic interventions, where induction of unconventional
class II-restricted CD8+ T cells that show antiviral efficacy may
be beneficial.Immunity 45, 917–930, October 18, 2016 927
EXPERIMENTAL PROCEDURES
Subjects
A total of 129 HIV-infected individuals were recruited from Massachusetts
General Hospital after providing informed consent. From those, 101 individuals
were defined as ‘‘HIV controllers:’’ HIV-infected individualswho spontaneously
control HIV infection in the absence of antiretroviral therapy for greater than 1
year. Additionally, 28 treatment-naive HIV progressors with plasma viral loads
of greater than 2,000 HIV RNA copies/mL were utilized (see also Tables S1 and
S2 and Supplemental Experimental Procedures).
HLA-DR CD8+ Elispot
Screening for class II-restricted HIV-specific CD8+ T cell responses and
epitope fine mapping was conducted by enzyme-linked immunospot (Elispot)
assay, using CD8+ T cells enriched by CD8 MACS MicroBeads selection (Mil-
tenyi). Antigen-presenting cells expressing the HLA-DRB1 of the subject con-
sisted of mouse lymphoblastoid cell line (LCL) fibroblasts stably transfected
with a plasmid encoding a single recombinant humanHLA-DRB1 variant span-
ning common Caucasian alleles: DRB1*01:01, *03:01, *04:01, *07:01, *11:01,
*13:01, and *15:01. LCL were split across 70 wells of a V-bottom 96-well plate
and pulsed with 10 mg/mL peptide. We used 66 individual overlapping pep-
tides (OLPs) spanning HIV Gag protein (clade B 2001 consensus-sequence)
tested in singlet and had 4 negative control wells without peptide. Plates
were incubated at 37C and 5% CO2 for 90 min and washed 63 to remove
any unbound peptide. We then cultured 20,000 LCL with 100,000 CD8+
T cells per well on a pre-coated interferon gamma (IFN-g) plate. As a positive
control, phytohemagglutinin (Sigma) was added at 1.8 mg/mL. The plates were
incubated overnight at 37C and 5% CO2 and processed as previously
described (Ranasinghe et al., 2013). We used the AID Elispot reader (Autoim-
mun Diagnostika GmbH) to determine the number of spot-forming cells per
100,000 CD8+ T cells. A HLA-DR restriction was considered positive only
if R3 times the mean background and also R3 times the standard deviation
of negative control wells. A caveat is that each OLP was tested only once
and some responses may be below the threshold for a ‘‘positive’’ result. To
rectify this, any responses deemed above or close to the positive threshold
were independently re-tested in quadruplicate.
HLA Class I and II Tetramers
Class II tetramers custom-manufactured by MBL International or made
in collaboration with Dr. James Moon included DR11-Gag41 (DRB1*11:01-
DRFYKTLRAEQASQEV) and DR01-Gag37 (DRB1*01:01-LNKIVRMYSPTSILD)
conjugated to either PE or APC. Class I tetramers were made in collaboration
with Dr. Soren Buus as described (Leisner et al., 2008). The class I tetramers
included B57-KF11 (KAFSPEVIPMF), B08-EI8 (EIYKRWII), and B27-KK10
(KRWIILGLNK) in either PE or APC. Tetramers were incubated with whole
PBMCs (25 min at 37C, 5% CO2) and then stained for viability and surface
markers prior to fixation. Tetramer staining of hybridomas was conducted with
the sameprotocol. Intracellular stainingwasused forGranzymeBand IFN-g us-
ing the Cytofix/Cytoperm kit (BD PharMingen) according to the manufacturer’s
instructions. All fixed sampleswere analyzedona LSRII flowcytometer (BDBio-
sciences) with FlowJo software (Treestar).
Functional Characterization of Class II-Restricted CD8+ T Cells
To determine HIV-specific cytokine secretion in response to peptide-HLA-DR
stimulus, whole PBMCs were incubated with 2 mg/mL of peptide pulsed onto
LCL or left unstimulated in the presence of anti-HLA-DR (azide-free clone
L243, Biolegend) to efficiently blockHLA class II recognition. BFA andmonensin
were added to prevent cytokine secretion. IFN-g secretion in response to pep-
tide stimulus was measured from CD8+ T cells. To confirm the restriction of
the CD8+ T cells, class I and class II tetramers were utilized. To determine prolif-
erative capacity, PBMCs were stained with carboxyfluorescein diacetate succi-
nimidyl ester (CFSE;MolecularProbes, Life Technologies) for 7min at 37C, then
washed. Appropriate class I and class II peptides were added at 0.1 mg/mL to
CFSE-labeled whole PBMCs for 7 days in RPMI 1640 medium in the absence
of IL-2 at 37C, 5% CO2. PHA was used as a positive control and the absence
of peptide stimulation was used as a negative control. After 7 days, cells were
labeled with appropriate tetramer in APC together with antibodies to CD3,
CD4, CD8, andCD25 and analyzed on a LSRII flow cytometer (BDBiosciences).928 Immunity 45, 917–930, October 18, 2016Chromium Release Assay
Chromium release assays were conducted with autologous targets (EBV-
transformed B cell lines, CD4+ T cells, and monocyte-derived macrophages),
as described in Supplemental Experimental Procedures. Activated autologous
CD4+ T cells were infected with HIV NL4-3 by spinoculation at 8003 g for 1 hr
at 37C and cultured for 48 hr at 37C and 5% CO2. Autologous monocyte-
derivedmacrophages were plated at 30,000 per well and VSV-G-pseudotyped
SIV mac251 VLPs were added 3 hr prior to HIV challenge to abrogate host re-
striction factors and subsequently increase HIV infectivity. Macrophages were
then infected with VSV-G-pseudotyped HIV NL4.3 expressing GFP by spino-
culation at 8003 g for 1 hr at 37C and cultured for 48 hr at 37C and 5%CO2.
The CXCR4-utilizing HIV-1 laboratory strain NL4-3 and its VSV-G pseudotyped
version were obtained from the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH.
48 hr after HIV infection, CD4+ T cells or macrophage target cells
were labeled with chromium for 1 hr at 37C and then washed 3 times.
Tetramer-sorted CD8+ T cells isolated from PBMCs or CD8+ T cell clones
were then added at the indicated effector-target ratios, and a standard
4–6 hr chromium release assay was performed as previously described
(Chen et al., 2012).
Single-Cell RNA-Seq
Whole-transcriptome amplification of single cells in 96-well plates was per-
formed with a modified SMART-Seq2 protocol, as described previously
(Trombetta et al., 2014). Samples were sequenced on an Illumina NextSeq
500 instrument using either 30-bp paired-end reads or 150-bp single-end
reads. RNA-seq reads were first trimmed using Trimmomatic (Bolger et al.,
2014) and then aligned to the RefSeq hg38 transcriptome and genome using
RSEM and TopHat. Considering only single-cell libraries in which we could
reconstruct a productive TCR alignment, we excluded from further analysis
genes and libraries with poor performance or coverage, leaving 205 cells
and 3,274 genes. Out of the 205 cells with reconstructed TCR sequences,
30 were CD4+ and 175 were CD8+ by flow cytometry gating. The TPM expres-
sion of CD4, CD8A, and CD8B transcripts between the CD4+ and CD8+ cells
was compared using Mann-Whitney-Wilcoxon test.
TCR a and b Chain Sequencing
In order to reconstruct CDR3 sequences from single-cell RNA-sequencing
data, we developed TrapeS (TCR Reconstruction Algorithm for Paired-End
Single cells), a software package for reconstruction of TCR sequences using
short (25 bp) single-cell paired-end RNA sequencing based on TopHat
genomic alignments (Supplemental Experimental Procedures). TrapeS is
available upon request.
TCR-Expressing T Cell Hybridomas
As previously described (White et al., 2000), an MSCV-derived retrovirus en-
coding GFP and the common TRBV2 V-domain fused to mouse Cb and either
the TRAV6 or TRAV26 domain fused mouse Ca was prepared. The virus was
used to transduce a TCR variant of the mouse T cell hybridoma that had
been previously transduced to express human CD8a chain. T cells expressing
high levels of TCR and CD8 were single cell cloned by FACS. 105 transduced
T cell hybridomas were placed in 250 mL culture wells that had been either
previously coated with an anti-mouse TCR Cb Mab (H57-597) or contained
105 HLA-DR11-bearing LCL cells and various concentrations of the Gag41
peptide. After overnight culture at 37C, the culture supernatants were as-
sayed for IL-2 using the IL2-dependent cell line HT2.
Statistical Analysis
Paired t tests and Mann-Whitney-Wilcoxon test were used to compare
different conditions, when each condition was tested in triplicate or greater.
All p values are two-sided and p < 0.05 was considered significant. Statistical
analysis and graphing were performed using GraphPad Prism 5.0 or R.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2016.09.015.
AUTHOR CONTRIBUTIONS
S.R. was responsible for the concept and conduct of the study; S.R., P.A.L.,
and B.D.W. contributed to the experimental design and data analysis; S.R.,
P.A.L., D.Z.S., R.B.J., F.D., C.N., and P.J. performed the experiments;
S.W.K. and A.K.S. conducted single-cell RNA-seq; M.B.C. and N.Y. computa-
tionally reconstructed TCR; G.M.C., F.C., J.W., A.M., and J.W.K. constructed
TCR hybridomas and performed SPR; K.P. and T.M.A. conducted viral
sequencing; H.S., D.E.K., and L.J.P. provided intellectual input and editorial
comments; B.D.W. provided clinical samples and oversight of the project;
S.R., P.A.L., and B.D.W. wrote the manuscript; and all authors contributed
to revisions.
ACKNOWLEDGMENTS
We thank all study participants, as well as A. Sette and J. Sidney for the LCL,
M.C. Carrington for HLA typing, and M. Nakayama for 5KC mouse hybrid-
omas. This study was funded by the Bill & Melinda Gates Foundation Collab-
oration for AIDS Vaccine Discovery (CAVD) grant APP1108533 to L.J.P.,
B.D.W, and S.R. S.R. is also supported by a CFAR Developmental Award
(NIH/NIAID 5P30AI060354). P.A.L. is supported by a HHMI International Stu-
dent Research Fellowship. D.E.K. is supported by a Research Scholar Career
Award of the Quebec Health Research Fund. T.M.A. and K.P. are supported by
NIAID grant AI104715. S.W.K. is supported by a NSF Graduate Research
Fellowship. A.K.S. is supported by the Ragon Institute, the Searle Scholars
Program, the Beckman Young Investigator Program, the NIH New Innovator
Award (DP2 OD020839), and NIH U24 AI11862-01 from NIAID. L.J.P. and
OHSU have a significant financial interest in Vir Bio, Inc., a company that
may have a commercial interest in the results of this research and technology.
The potential individual and institutional conflicts of interest have been re-
viewed and are being managed by OHSU. The content of this publication
does not necessarily reflect the views or policies of the Department of Health
and Human Services, U.S. Army, or Department of Defense, nor does mention
of trade names, commercial products, or organizations imply endorsement by
the U.S. Government. The funders had no role in study design, data collection
and interpretation, or the decision to submit the work for publication.
Received: June 3, 2016
Revised: August 9, 2016
Accepted: August 15, 2016
Published: October 18, 2016
REFERENCES
Almeida, J.R., Price, D.A., Papagno, L., Arkoub, Z.A., Sauce, D., Bornstein, E.,
Asher, T.E., Samri, A., Schnuriger, A., Theodorou, I., et al. (2007). Superior con-
trol of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunc-
tionality, and clonal turnover. J. Exp. Med. 204, 2473–2485.
Benati, D., Galperin, M., Lambotte, O., Gras, S., Lim, A., Mukhopadhyay, M.,
Noue¨l, A., Campbell, K.A., Lemercier, B., Claireaux, M., et al. (2016). Public
T cell receptors confer high-avidity CD4 responses to HIV controllers.
J. Clin. Invest. 126, 2093–2108.
Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible
trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120.
Carrington, M., and Walker, B.D. (2012). Immunogenetics of spontaneous
control of HIV. Annu. Rev. Med. 63, 131–145.
Chen, H., Ndhlovu, Z.M., Liu, D., Porter, L.C., Fang, J.W., Darko, S.,
Brockman, M.A., Miura, T., Brumme, Z.L., Schneidewind, A., et al. (2012).
TCR clonotypes modulate the protective effect of HLA class I molecules in
HIV-1 infection. Nat. Immunol. 13, 691–700.
Emu, B., Sinclair, E., Hatano, H., Ferre, A., Shacklett, B., Martin, J.N., McCune,
J.M., and Deeks, S.G. (2008). HLA class I-restricted T-cell responses
may contribute to the control of human immunodeficiency virus infection,
but such responses are not always necessary for long-term virus control.
J. Virol. 82, 5398–5407.
Fellay, J., Shianna, K.V., Ge, D., Colombo, S., Ledergerber, B., Weale, M.,
Zhang, K., Gumbs, C., Castagna, A., Cossarizza, A., et al. (2007). A whole-genome association study of major determinants for host control of HIV-1.
Science 317, 944–947.
Hansen, S.G., Sacha, J.B., Hughes, C.M., Ford, J.C., Burwitz, B.J., Scholz, I.,
Gilbride, R.M., Lewis, M.S., Gilliam, A.N., Ventura, A.B., et al. (2013).
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.
Science 340, 1237874.
Hansen, S.G., Wu, H.L., Burwitz, B.J., Hughes, C.M., Hammond, K.B.,
Ventura, A.B., Reed, J.S., Gilbride, R.M., Ainslie, E., Morrow, D.W., et al.
(2016). Broadly targeted CD8+ T cell responses restricted by major histocom-
patibility complex E. Science 351, 714–720.
Heemskerk, M.H., de Paus, R.A., Lurvink, E.G., Koning, F., Mulder, A.,
Willemze, R., van Rood, J.J., and Falkenburg, J.H. (2001). Dual HLA class I
and class II restricted recognition of alloreactive T lymphocytes mediated by
a single T cell receptor complex. Proc. Natl. Acad. Sci. USA 98, 6806–6811.
Hirosawa, T., Torikai, H., Yanagisawa, M., Kamei, M., Imahashi, N., Demachi-
Okamura, A., Tanimoto, M., Shiraishi, K., Ito, M., Miyamura, K., et al. (2011).
Mismatched human leukocyte antigen class II-restricted CD8+ cytotoxic
T cells may mediate selective graft-versus-leukemia effects following alloge-
neic hematopoietic cell transplantation. Cancer Sci. 102, 1281–1286.
Horton, H., Frank, I., Baydo, R., Jalbert, E., Penn, J., Wilson, S., McNevin, J.P.,
McSweyn, M.D., Lee, D., Huang, Y., et al. (2006). Preservation of T cell
proliferation restricted by protective HLA alleles is critical for immune control
of HIV-1 infection. J. Immunol. 177, 7406–7415.
Iglesias, M.C., Almeida, J.R., Fastenackels, S., van Bockel, D.J., Hashimoto,
M., Venturi, V., Gostick, E., Urrutia, A., Wooldridge, L., Clement, M., et al.
(2011). Escape from highly effective public CD8+ T-cell clonotypes by HIV.
Blood 118, 2138–2149.
Kaslow, R.A., Carrington, M., Apple, R., Park, L., Mun˜oz, A., Saah, A.J.,
Goedert, J.J., Winkler, C., O’Brien, S.J., Rinaldo, C., et al. (1996). Influence
of combinations of human major histocompatibility complex genes on the
course of HIV-1 infection. Nat. Med. 2, 405–411.
Kiepiela, P., Leslie, A.J., Honeyborne, I., Ramduth, D., Thobakgale, C., Chetty,
S., Rathnavalu, P., Moore, C., Pfafferott, K.J., Hilton, L., et al. (2004). Dominant
influence of HLA-B in mediating the potential co-evolution of HIV and HLA.
Nature 432, 769–775.
Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I.,
Moodley, E., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., et al.
(2007). CD8+ T-cell responses to different HIV proteins have discordant asso-
ciations with viral load. Nat. Med. 13, 46–53.
Leisner, C., Loeth, N., Lamberth, K., Justesen, S., Sylvester-Hvid, C., Schmidt,
E.G., Claesson, M., Buus, S., and Stryhn, A. (2008). One-pot, mix-and-read
peptide-MHC tetramers. PLoS ONE 3, e1678.
Mason, D. (1994). Allelic exclusion of alpha chains in TCRs. Int. Immunol. 6,
881–885.
Matechak, E.O., Killeen, N., Hedrick, S.M., and Fowlkes, B.J. (1996). MHC
class II-specific T cells can develop in the CD8 lineage when CD4 is absent.
Immunity 4, 337–347.
Mendoza, D., Royce, C., Ruff, L.E., Ambrozak, D.R., Quigley, M.F., Dang, T.,
Venturi, V., Price, D.A., Douek, D.C., Migueles, S.A., and Connors, M.
(2012). HLA B*5701-positive long-term nonprogressors/elite controllers are
not distinguished from progressors by the clonal composition of HIV-specific
CD8+ T cells. J. Virol. 86, 4014–4018.
Migueles, S.A., Sabbaghian, M.S., Shupert, W.L., Bettinotti, M.P., Marincola,
F.M., Martino, L., Hallahan, C.W., Selig, S.M., Schwartz, D., Sullivan, J., and
Connors, M. (2000). HLA B*5701 is highly associated with restriction of virus
replication in a subgroup of HIV-infected long term nonprogressors. Proc.
Natl. Acad. Sci. USA 97, 2709–2714.
Mizuochi, T., Tentori, L., Sharrow, S.O., Kruisbeek, A.M., and Singer, A. (1988).
Differentiation of Ia-reactive CD8+ murine T cells does not require Ia engage-
ment. Implications for the role of CD4 and CD8 accessory molecules in T cell
differentiation. J. Exp. Med. 168, 437–442.
Neefjes, J., Jongsma, M.L., Paul, P., and Bakke, O. (2011). Towards a systems
understanding ofMHC class I andMHC class II antigen presentation. Nat. Rev.
Immunol. 11, 823–836.Immunity 45, 917–930, October 18, 2016 929
Pearce, E.L., Shedlock, D.J., and Shen, H. (2004). Functional characterization
of MHC class II-restricted CD8+CD4- andCD8-CD4- T cell responses to infec-
tion in CD4-/- mice. J. Immunol. 173, 2494–2499.
Pereyra, F., Jia, X., McLaren, P.J., Telenti, A., de Bakker, P.I., Walker, B.D.,
Ripke, S., Brumme, C.J., Pulit, S.L., Carrington, M., et al.; International HIV
Controllers Study (2010). The major genetic determinants of HIV-1 control
affect HLA class I peptide presentation. Science 330, 1551–1557.
Ranasinghe, S., and Walker, B.D. (2013). Programming CMV for vaccine vec-
tor design. Nat. Biotechnol. 31, 811–812.
Ranasinghe, S., Flanders, M., Cutler, S., Soghoian, D.Z., Ghebremichael, M.,
Davis, I., Lindqvist, M., Pereyra, F., Walker, B.D., Heckerman, D., and
Streeck, H. (2012). HIV-specific CD4 T cell responses to different viral proteins
have discordant associations with viral load and clinical outcome. J. Virol. 86,
277–283.
Ranasinghe, S., Cutler, S., Davis, I., Lu, R., Soghoian, D.Z., Qi, Y., Sidney, J.,
Kranias, G., Flanders, M.D., Lindqvist, M., et al. (2013). Association of HLA-
DRB1-restricted CD4+ T cell responses with HIV immune control. Nat. Med.
19, 930–933.
Riou, C., Burgers, W.A., Mlisana, K., Koup, R.A., Roederer, M., Abdool Karim,
S.S., Williamson, C., and Gray, C.M. (2014). Differential impact of magnitude,
polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses
on HIV set point. J. Virol. 88, 1819–1824.
Rist, M., Smith, C., Bell, M.J., Burrows, S.R., and Khanna, R. (2009). Cross-
recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new para-
digm for self-/nonself-recognition. Blood 114, 2244–2253.
Schwartz, O., Mare´chal, V., Le Gall, S., Lemonnier, F., and Heard, J.M. (1996).
Endocytosis of major histocompatibility complex class I molecules is induced
by the HIV-1 Nef protein. Nat. Med. 2, 338–342.930 Immunity 45, 917–930, October 18, 2016Scriba, T.J., Purbhoo, M., Day, C.L., Robinson, N., Fidler, S., Fox, J., Weber,
J.N., Klenerman, P., Sewell, A.K., and Phillips, R.E. (2005). Ultrasensitive
detection and phenotyping of CD4+ T cells with optimized HLA class II
tetramer staining. J. Immunol. 175, 6334–6343.
Shimizu, T., and Takeda, S. (1997). CD8 T cells from major histocompatibility
complex class II-deficient mice respond vigorously to class II molecules in a
primary mixed lymphocyte reaction. Eur. J. Immunol. 27, 500–508.
Southwood, S., Sidney, J., Kondo, A., del Guercio, M.F., Appella, E., Hoffman,
S., Kubo, R.T., Chesnut, R.W., Grey, H.M., and Sette, A. (1998). Several com-
mon HLA-DR types share largely overlapping peptide binding repertoires.
J. Immunol. 160, 3363–3373.
Suzuki, H., Eshima, K., Takagaki, Y., Hanaoka, S., Katsuki, M., Yokoyama, M.,
Hasegawa, T., Yamazaki, S., and Shinohara, N. (1994). Origin of a T cell clone
with a mismatched combination of MHC restriction and coreceptor expres-
sion. J. Immunol. 153, 4496–4507.
Trombetta, J.J., Gennert, D., Lu, D., Satija, R., Shalek, A.K., and Regev, A.
(2014). Preparation of single-cell RNA-seq libraries for next generation
sequencing. Curr. Protoc. Mol. Biol. 107, 1–17.
Tyznik, A.J., Sun, J.C., and Bevan, M.J. (2004). The CD8 population in
CD4-deficient mice is heavily contaminated with MHC class II-restricted
T cells. J. Exp. Med. 199, 559–565.
van der Merwe, P.A., and Davis, S.J. (2003). Molecular interactions mediating
T cell antigen recognition. Annu. Rev. Immunol. 21, 659–684.
White, J., Kappler, J., and Marrack, P. (2000). Production and characterization
of T cell hybridomas. Methods Mol. Biol. 134, 185–193.
